Literature DB >> 6452013

The relationship between the hyperplastic pancreatic islet and insulin insensitivity in obesity.

R J Mahler.   

Abstract

In summary, the present review provides evidence in support of the proposition that pancreatic islet cell hyperplasia precedes the development of insulin insensitivity in the obese mouse and, it is likely, that similar events occur in obese humans. Moreover, the hyperplastic pancreatic islet appears to be responsible for the development of insulin insensitivity, since suppression of the hyperplastic islet, by either alloxan or streptozotocin administration to the obese mouse, results in amelioration of insulin insensitivity in vivo. Since no change occurred in the degree of obesity or in adipocyte cell size or number, it is evident that insulin sensitivity is independent of obesity per se. Hence, although obesity and insulin insensitivity frequently co-exist, insulin insensitivity is independent of obesity and is due rather to the presence of pancreatic islet cell hyperplasia. Light and electron microscopy of the hyperplastic pancreatic islets of the obese mouse reveal increased numbers of A- B- and D-cells. Islet suppression with alloxan or streptozotocin results in the selective reduction of B-cells with preservation of A- and D-cells. Therefore, restoration of insulin sensitivity in the obese mouse following pancreatic islet cell suppression appears to be directly related to suppression of B-cell hypersecretion. Biochemical studies of muscle and adipose tissues from the obese mouse reveal profound insulin unresponsiveness without clear cut improvement in vitro following pancreatic islet cell suppression and restoration of insulin sensitivity in vivo. These data are consistent with a relatively modest reduction in the number of available insulin receptors upon these tissues in relation to the marked insulin resistance and imply an impairment of insulin action beyond the insulin receptor interaction [either transport or intracellular action(s)] as the major site(s) of insulin resistance in the muscle and adipose tissues of obese mice. Conversely a reduction of insulin receptors upon hepatocytes of obese mice and their improvement following a reduction of B-cell hypersecretion support the proposition that the number of available insulin receptors may be the major site for the regulation of insulin action upon that tissue. Finally, evidence is presented which suggests that an inability of insulin to limit hepatic gluconeogenesis may be the predominant cause of insulin insensitivity in the obese mouse.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6452013     DOI: 10.1007/bf02056101

Source DB:  PubMed          Journal:  Acta Diabetol Lat        ISSN: 0001-5563


  66 in total

1.  Forearm metabolism in obesity and its response to intra-arterial insulin. Evidence for adaptive hyperinsulinism.

Authors:  D RABINOWITZ; K L ZIERLER
Journal:  Lancet       Date:  1961-09-23       Impact factor: 79.321

Review 2.  Principles of membrane receptor physiology and their application to clinical medicine.

Authors:  R J Pollet; G S Levey
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

3.  Thymic lymphocytes in obese (ob-ob) mice. A mirror of the insulin receptor defect in liver and fat.

Authors:  A H Soll; I D Goldfine; J Roth; C R Kahn
Journal:  J Biol Chem       Date:  1974-07-10       Impact factor: 5.157

4.  Glucagon: role in the hyperglycemia of diabetes mellitus.

Authors:  R Dobbs; H Sakurai; H Sasaki; G Faloona; I Valverde; D Baetens; L Orci; R Unger
Journal:  Science       Date:  1975-02-14       Impact factor: 47.728

5.  Insulin secretion in obesity.

Authors:  R A Kreisberg; B R Boshell; J DiPlacido; R F Roddam
Journal:  N Engl J Med       Date:  1967-02-09       Impact factor: 91.245

6.  The role of adipose cell size and adipose tissue insulin sensitivity in the carbohydrate intolerance of human obesity.

Authors:  L B Salans; J L Knittle; J Hirsch
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

7.  The effect of experimental insulin deficiency on glucagon secretion.

Authors:  W A Müller; G R Faloona; R H Unger
Journal:  J Clin Invest       Date:  1971-09       Impact factor: 14.808

8.  Insulin-dependent regulation of insulin receptor concentrations: a direct demonstration in cell culture.

Authors:  J R Gavin; J Roth; D M Neville; P de Meyts; D N Buell
Journal:  Proc Natl Acad Sci U S A       Date:  1974-01       Impact factor: 11.205

9.  Downregulation of insulin receptors in obese man.

Authors:  J P Wigand; W G Blackard
Journal:  Diabetes       Date:  1979-04       Impact factor: 9.461

10.  Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic sujbjects.

Authors:  M J Perley; D M Kipnis
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

View more
  5 in total

1.  Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice.

Authors:  A D Dobrian; Q Ma; J W Lindsay; K A Leone; K Ma; J Coben; E V Galkina; J L Nadler
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-11-16       Impact factor: 4.310

Review 2.  The role of exogenous insulin in the complex of hepatic lipidosis and ketosis associated with insulin resistance phenomenon in postpartum dairy cattle.

Authors:  A Hayirli
Journal:  Vet Res Commun       Date:  2006-10       Impact factor: 2.459

3.  How Western Diet And Lifestyle Drive The Pandemic Of Obesity And Civilization Diseases.

Authors:  Wolfgang Kopp
Journal:  Diabetes Metab Syndr Obes       Date:  2019-10-24       Impact factor: 3.168

4.  Development of Obesity: The Driver and the Passenger.

Authors:  Wolfgang Kopp
Journal:  Diabetes Metab Syndr Obes       Date:  2020-11-27       Impact factor: 3.168

5.  (-)-Epicatechin Reverses Glucose Intolerance in Rats Housed at Thermoneutrality.

Authors:  Ji Hye Chun; Melissa M Henckel; Leslie A Knaub; Sara E Hull; Greg B Pott; David G Ramirez; Jane E-B Reusch; Amy C Keller
Journal:  Planta Med       Date:  2022-07-01       Impact factor: 3.007

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.